Anti-CD38 antibody for refractory acquired hemophilia A

被引：4

作者：

Liu, Wei ^{[1
]}

Liu, Jiaying ^{[1
]}

Xue, Feng ^{[1
]}

Yang, Renchi ^{[1
]}

Zhang, Lei ^{[1
,2
,3
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin Key Lab Gene Therapy Blood Dis, State Key Lab Expt Hematol,Natl Clin Res Ctr Blood, Tianjin, Peoples R China

[2] Tianjin Inst Hlth Sci, Tianjin, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2023年 / 21卷 / 06期

基金：

中国国家自然科学基金;

关键词：

acquired hemophilia A; daratumumab; factor VIII; FVIII inhibitor; immunosuppression therapy;

D O I：

10.1016/j.jtha.2023.03.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with acquired hemophilia A (AHA) are prone to bleeding symptoms due to decrease in factor (F)VIII activity caused by FVIII antibodies. Risk of severe bleeding in AHA is higher than that of hereditary hemophilia, so clearance of FVIII inhibitors is necessary for treatment, especially in refractory AHA. Daratumumab is currently a popular monoclonal antibody for clearing plasma cells and antibodies and is often used in multiple myeloma. Based on this, we report, for the first time, that 4 patients with AHA who were refractory to first-and second-line therapy were treated with dar-atumumab and achieved good responses. None of our 4 patients developed serious infections. Thus, we provide a new approach for treating refractory AHA.

引用

页码：1515 / 1518

页数：4

共 50 条

[1] IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure
Gavriatopoulou, Maria
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Kanellias, Nikolaos
Eleutherakis-Papaiakovou, Evangelos
Dialoupi, Ioanna
Theodorakakou, Foteini
Roussou, Maria
Terpos, Evangelos
Kastritis, Efstathios
Dimopoulos, Meletios A.
BLOOD, 2020, 136
[2] Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
Li, Weiwang
Zhang, Lele
Pan, Hong
Gao, Zhen
Li, Jianping
Nie, Neng
Zhao, Xin
Huang, Jinbo
Zhao, Jingyu
Yu, Xiao
Kuang, Zhexiang
Fang, Liwei
Ge, Meili
Yuan, Weiping
Shi, Jun
BLOOD, 2024, 144 : 2697 - 2697
[3] The Anti-CD38 Antibody Therapy in Multiple Myeloma
Petrucci, Maria Teresa
Vozella, Federico
CELLS, 2019, 8 (12)
[4] Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
Benfaremo, Devis
Gabrielli, Armando
CELLS, 2020, 9 (01)
[5] A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia
Chen, Yunfei
Xu, Yanmei
Li, Huiyuan
Sun, Ting
Cao, Xuan
Wang, Yuhua
Xue, Feng
Liu, Wei
Liu, Xiaofan
Dong, Huan
Fu, Rongfeng
Dai, Xinyue
Wang, Wentian
Ma, Yueshen
Song, Zhen
Chi, Ying
Ju, Mankai
Gu, Wenjing
Pei, Xiaolei
Yang, Renchi
Zhang, Lei
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (23): : 2178 - 2190
[6] DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
Richardson, P.
Lokhorst, H.
Palumbo, A.
Nahi, H.
Laubach, J.
Gimsing, P.
Lisby, S.
Cakana, A.
Brun, N. Constantin
Plesner, T.
DRUGS OF THE FUTURE, 2013, 38 (08) : 545 - 554
[7] Transfusion management for patients taking an anti-CD38 monoclonal antibody
Bub, Carolina Bonet
dos Reis, Isabel Nagle
Aravechia, Maria Giselda
Santos, Leandro Dinalli
Bastos, Eduardo Peres
Kutner, Jose Mauro
Castilho, Lilian
HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (01) : 25 - 29
[8] Therapeutic Anti-CD38 Monoclonal Antibody as a Cause of Panreactive Antibody Screening in Immunohematology
Luzzi, J.
Brito, C. A.
Gimenez, N. T.
Navarro-Xavier, R. A.
Jesuino, D. B.
TRANSFUSION, 2016, 56 : 139A - 139A
[9] Anti-CD38 autoantibodies and diabetes
Raymondjean, M
M S-MEDECINE SCIENCES, 1998, 14 (10): : 1132 - 1133
[10] The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, Laura
Perez, Cristina
Zabaleta, Aintzane
Manrique, Irene
Alignani, Diego
Ajona, Daniel
Blanco, Laura
Lasa, Marta
Maiso, Patricia
Rodriguez, Idoia
Garate, Sonia
Jelinek, Tomas
Segura, Victor
Moreno, Cristina
Merino, Juana
Rodriguez-Otero, Paula
Panizo, Carlos
Prosper, Felipe
San-Miguel, Jesus F.
Paiva, Bruno
CLINICAL CANCER RESEARCH, 2019, 25 (10) : 3176 - 3187

← 1 2 3 4 5 →